APON(SZ:300753)2019-03-15 16:00Financial Performance - The company's operating revenue for 2018 was CNY 298,033,812.31, representing a 20.70% increase compared to CNY 246,922,317.24 in 2017[18]. - The net profit attributable to shareholders for 2018 was CNY 70,089,798.68, up 21.01% from CNY 57,921,514.33 in 2017[18]. - The net profit after deducting non-recurring gains and losses was CNY 66,909,349.89, reflecting a 20.50% increase from CNY 55,527,932.91 in 2017[18]. - The net cash flow from operating activities for 2018 was CNY 78,127,068.21, an increase of 16.48% compared to CNY 67,075,966.07 in 2017[18]. - The total assets at the end of 2018 reached CNY 687,955,326.39, a significant increase of 106.44% from CNY 333,255,051.54 at the end of 2017[18]. - The net assets attributable to shareholders at the end of 2018 were CNY 604,857,955.16, up 122.51% from CNY 271,838,132.81 at the end of 2017[18]. - The basic earnings per share for 2018 were CNY 1.16, a 20.83% increase from CNY 0.96 in 2017[18]. - The diluted earnings per share for 2018 were also CNY 1.16, reflecting the same growth of 20.83% compared to CNY 0.96 in 2017[18]. - The weighted average return on equity for 2018 was 22.84%, a slight decrease of 0.77% from 23.61% in 2017[18]. - The company reported a loss from the disposal of non-current assets of CNY 50,922.59 in 2018, compared to a loss of CNY 9,231.60 in 2017[24]. Research and Development - The report outlines the company's commitment to research and development in new products and technologies within the medical field[10]. - The company achieved a research and development investment of RMB 20.98 million in 2018, representing a 4.78% increase year-over-year, and accounting for 7.04% of the annual revenue[50]. - The company has maintained a consistent focus on R&D and product innovation to enhance its market position in the medical device industry[28]. - The company holds 63 patents, including 6 invention patents, and has established a strong R&D capability recognized as a high-tech enterprise by Jiangsu Province[50]. - The company is focusing on three target segments in pain management: postoperative analgesia, labor analgesia, and tumor analgesia[101]. - The company is committed to developing a leading brand in pain management and nasal care medical devices through continuous technological innovation and high-quality service[97]. Market Strategy and Expansion - The company is focused on market expansion and strategic acquisitions to enhance its competitive position in the healthcare industry[10]. - The company expanded its market presence by adding 263 new distributors and 296 new terminal hospitals, including 91 tertiary hospitals, during the reporting period[52]. - The company is actively developing online sales channels for its nasal care products, utilizing internet marketing strategies to enhance brand recognition[55]. - The company aims to expand its market presence by establishing regional marketing centers in 20 key cities, including Beijing and Guangzhou[162]. - Future product development will focus on pain management systems and nasal care products, leveraging new technologies such as AI and medical information systems[159]. Corporate Governance and Compliance - The report emphasizes the importance of risk awareness regarding future plans and development strategies, indicating potential discrepancies between plans, forecasts, and commitments[5]. - The company has confirmed that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy[4]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible personnel, including the chairman and accounting manager[4]. - The company is committed to improving corporate governance and transparency in accordance with relevant laws and regulations[112]. - The company has established a mechanism to strengthen investor returns and ensure the proper use of raised funds[183]. Product Development and Innovation - The company launched a new product, the "Sensitive Companion Probiotic Powder Solid Beverage," during the reporting period[38]. - The company launched a high-osmotic buffered seawater nasal care spray, achieving positive market results[108]. - The company is focusing on the development of new products, including a portable electric infusion pump and a multi-channel pediatric brain oxygen monitoring system[106]. - The company has developed various software for its medical devices, enhancing its product offerings[85]. Shareholder and Stock Management - The company plans to distribute a cash dividend of 4.00 RMB per 10 shares to all shareholders, based on a total of 80,800,000 shares[5]. - The company strictly adhered to the lock-up commitments for shareholders, ensuring no transfer or management of shares for 36 months post-IPO[179]. - Shareholders are restricted from reducing their holdings for two years after the lock-up period, with a maximum reduction of 5% of the total share capital post-IPO[180]. - The company will implement measures to stabilize stock prices if the average stock price falls below the latest audited net asset value per share for 20 consecutive trading days[180]. - The company plans to repurchase shares to stabilize stock prices, adhering to relevant laws and regulations[180]. Financial Structure and Investment - The company aims to optimize its financial structure by utilizing low-risk investments to improve capital efficiency and returns, while also considering bank loans or capital market financing as needed[166]. - The company will increase R&D investment to enhance its independent innovation capabilities and improve the conversion of R&D results into production[169]. - The company reported a significant increase in monetary funds due to the IPO, with cash reserves rising by ¥266,319,682.67[144]. - The company has not utilized any of the raised funds from the IPO as of the end of 2018, with a balance of ¥264,081,035.29 remaining[150].